Sign In
Buy MLTX
$19.02
-0.340 (-1.76%)
At Close: Jul 24, 2026
MLTX Investors with Losses Encouraged to Contact the Firm San Francisco, California--(Newsfile Corp. - November 27, 2025) - MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology c
New York, New York--(Newsfile Corp. - November 27, 2025) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized law firm,
MLTX Deadline: MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
11:48am, Thursday, 27'th Nov 2025
NEW YORK , Nov. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 202
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
10:10am, Thursday, 27'th Nov 2025
LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“
MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2
New York, New York--(Newsfile Corp. - November 26, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) bet
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on beh
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
SAN FRANCISCO , Nov. 26, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its sh
New York, New York--(Newsfile Corp. - November 26, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: M
MLTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 25, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has be
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Company: MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-1
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
09:56am, Tuesday, 25'th Nov 2025
LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) fo
